Hear from inventors from the National Cancer Institute and the Frederick National Laboratory about technologies primed for commercialization and/or collaboration; great opportunity for biotech stakeholders and companies of all sizes, [….]
Context Therapeutics Inc., a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, today announced the successful completion of ONA-XR (onapristone extended release) manufacturing process optimization pursuant to the collaboration agreement entered into between the parties in March 2020.
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy
Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate
Bethesda’s Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets
TCR² Therapeutics Acquires Cell Therapy Manufacturing Facility & New VP of Technical Operations, Aaron Vernon
85,000 square foot state-of-the-art facility being built in Rockville, MarylandAccelerates TCR2s commercial-scale manufacturing timelines with production anticipated in 2023Aaron Vernon hired…
The AIM-HI Accelerator Fund, a spin-off of the National Foundation for Cancer Research, aims to award $1 million to a female-led startup focused on meeting unmet needs across the oncology landscape. The organization is currently accepting applications for its 2021 Women’s Venture Competition.
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without [….]
Cancer genomics company Personal Genome Diagnostics Inc. (PGDx) secured $103 million in a Series C financing round. Proceeds from the financial infusion will be used to expand the company’s tissue-based and liquid biopsy portfolio and its global commercial footprint to support growth.
Lisa Tibbetts received a Master’s degree in Biotechnology from Georgetown University’s Department of Microbiology. She did her thesis in Usagi data mapping, pharmacovigilance, and artificial intelligence. She is also a graduate of Columbia University, Northwestern University, and Thomas Jefferson High School for Science and Technology and has worked in oncology, neurology, and most recently, satellite engineering.
Born and raised in gang-infested South Central Los Angeles, I was surrounded by compassionate and risk-taking individuals who recognized and fertilized my love, talent, and academic prowess. Collectively my tribe, for it takes one to raise one, helped provide me with unimaginable opportunities to excel and continue the fight for an abundant life through health, social awareness, and artistic expression. I, a Man who is also Bold and Black, am a product of their courage, compassion, endurance, vision, and love – Stephen M. Jackson, PhD